Porfyris O, Kalomoiris P
Department of Urology, General Hospital of Laconia, Sparta, Greece.
J BUON. 2013 Oct-Dec;18(4):809-17.
Chemotherapy is the conventional treatment for castration-resistant prostate cancer (CRPC) which provides only modest benefits. In the last few years, immunotherapy has emerged as an exciting therapeutic modality for advanced prostate cancer. Several characteristics of prostate cancer make it an ideal target for immunotherapy, and FDA approved recently sipuleucel-T based on improvement in overall survival (OS) in patients with CRPC. Current trials investigate the role of various immunological approaches in the treatment of prostate cancer, as far as the clinical benefit they provide is concerned and also deal with the issue of the measurability of this benefit. Future studies will focus on the combination of immunotherapeutic agents with conventional treatments in an effort to optimize patient outcomes.
化疗是去势抵抗性前列腺癌（CRPC）的传统治疗方法，其疗效有限。在过去几年中，免疫疗法已成为晚期前列腺癌令人振奋的治疗方式。前列腺癌的几个特征使其成为免疫疗法的理想靶点，美国食品药品监督管理局（FDA）最近基于CRPC患者总生存期（OS）的改善批准了sipuleucel-T。就目前所提供的临床益处而言，当前的试验正在研究各种免疫治疗方法在前列腺癌治疗中的作用，同时也在探讨这种益处的可衡量性问题。未来的研究将集中于免疫治疗药物与传统治疗方法的联合，以努力优化患者的治疗效果。
